Profile data is unavailable for this security.
About the company
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
- Revenue in USD (TTM)15.97m
- Net income in USD-107.69m
- Incorporated2020
- Employees136.00
- LocationLiquidia Corp419 Davis Drive, Suite 100MORRISVILLE 27560United StatesUSA
- Phone+1 (919) 328-4400
- Fax+1 (919) 328-4402
- Websitehttps://www.liquidia.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Avid Bioservices Inc | 139.91m | -140.75m | 621.19m | 371.00 | -- | 10.20 | -- | 4.44 | -2.22 | -2.22 | 2.21 | 0.9579 | 0.355 | 3.57 | 4.92 | 377,118.60 | -35.72 | -0.826 | -56.03 | -1.20 | 5.23 | 19.26 | -100.60 | -2.14 | 1.04 | -4.30 | 0.727 | -- | -6.27 | 21.15 | -54,444.79 | -- | 84.15 | -- |
Emergent Biosolutions Inc | 1.19bn | -565.30m | 629.87m | 1.60k | -- | 0.9487 | -- | 0.5314 | -10.87 | -10.87 | 22.86 | 12.67 | 0.4988 | 1.99 | 6.09 | 740,875.00 | -23.79 | -2.94 | -38.89 | -3.66 | 41.19 | 53.24 | -47.69 | -5.95 | 0.5538 | 0.0636 | 0.5771 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
Kalvista Pharmaceuticals Inc | 0.00 | -126.64m | 639.75m | 150.00 | -- | 3.08 | -- | -- | -3.40 | -3.40 | 0.00 | 4.86 | 0.00 | -- | -- | 0.00 | -60.51 | -40.63 | -66.52 | -43.67 | -- | -- | -- | -2,972.81 | -- | -- | 0.00 | -- | -- | -- | -36.31 | -- | -16.34 | -- |
Sinovac Biotech Ltd | 448.27m | -105.90m | 639.90m | 3.04k | -- | -- | -- | 1.43 | -1.08 | -1.08 | 4.19 | 87.41 | 0.0323 | 1.13 | 0.9175 | 147,602.60 | -1.86 | 36.14 | -2.80 | 58.37 | 59.51 | 90.77 | -57.63 | 65.87 | 10.18 | -- | 0.0207 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
SIGA Technologies Inc | 157.02m | 79.26m | 640.81m | 45.00 | 8.22 | 3.88 | 8.02 | 4.08 | 1.10 | 1.10 | 2.20 | 2.32 | 0.7354 | 0.3631 | 10.32 | 3,489,424.00 | 37.12 | 22.34 | 47.49 | 27.56 | 87.71 | 88.65 | 50.48 | 41.14 | 2.19 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
PetIQ Inc | 1.12bn | 7.34m | 663.17m | 1.93k | 103.38 | 2.80 | 12.22 | 0.5922 | 0.2156 | 0.2156 | 36.40 | 7.95 | 1.29 | 4.58 | 5.67 | 579,376.60 | 0.8933 | -4.32 | 1.14 | -5.23 | 23.66 | 20.05 | 0.6951 | -3.66 | 1.25 | 1.84 | 0.6517 | -- | 19.58 | 15.83 | 104.42 | -- | 4.96 | -- |
Evolus Inc | 219.70m | -60.00m | 748.20m | 279.00 | -- | 40.35 | -- | 3.41 | -1.05 | -1.05 | 3.82 | 0.2962 | 1.14 | 3.86 | 7.62 | 804,750.90 | -31.06 | -40.92 | -40.14 | -59.74 | 69.28 | 65.43 | -27.31 | -80.46 | 2.96 | -2.90 | 0.8674 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
Phibro Animal Health Corp | 999.56m | 13.16m | 770.38m | 1.92k | 58.55 | 2.85 | 15.81 | 0.7707 | 0.3249 | 0.3249 | 24.68 | 6.67 | 1.03 | 2.42 | 6.37 | 520,606.30 | 1.35 | 5.46 | 1.66 | 6.83 | 30.33 | 31.41 | 1.32 | 5.11 | 1.67 | 2.26 | 0.6427 | 42.99 | 3.78 | 3.59 | -33.69 | -13.56 | 22.80 | 3.71 |
Pliant Therapeutics Inc | 248.00k | -170.74m | 775.79m | 158.00 | -- | 1.77 | -- | 3,128.19 | -2.86 | -2.86 | 0.0042 | 7.25 | 0.0004 | -- | 0.0701 | 1,569.62 | -30.50 | -33.24 | -32.04 | -35.39 | -- | -- | -68,847.98 | -360.29 | -- | -- | 0.0642 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
Liquidia Corp | 15.97m | -107.69m | 865.80m | 136.00 | -- | 10.02 | -- | 54.22 | -1.57 | -1.57 | 0.2359 | 1.13 | 0.098 | -- | 4.77 | 117,404.40 | -66.06 | -55.02 | -72.44 | -62.69 | 76.82 | 82.18 | -674.42 | -474.59 | 7.50 | -28.61 | 0.4944 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
Harrow Inc | 138.68m | -31.33m | 889.86m | 315.00 | -- | 14.69 | -- | 6.42 | -0.9079 | -0.9079 | 4.09 | 1.71 | 0.5406 | 4.21 | 6.75 | 440,244.40 | -12.21 | -10.86 | -13.79 | -12.71 | 69.77 | 70.75 | -22.59 | -15.35 | 2.75 | -0.3302 | 0.7536 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
Pacira Biosciences Inc | 681.75m | 70.47m | 977.00m | 711.00 | 16.20 | 1.09 | 6.74 | 1.43 | 1.30 | 1.30 | 12.11 | 19.18 | 0.4389 | 1.93 | 7.00 | 958,866.40 | 4.54 | 3.35 | 4.84 | 3.98 | 73.15 | 72.63 | 10.34 | 8.57 | 4.78 | 51.11 | 0.3684 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
Tarsus Pharmaceuticals Inc | 42.56m | -148.21m | 1.04bn | 244.00 | -- | 3.76 | -- | 24.34 | -4.72 | -4.72 | 1.35 | 7.29 | 0.1519 | -- | 2.63 | 174,430.30 | -52.88 | -31.56 | -58.73 | -33.82 | 92.37 | -- | -348.22 | -242.59 | 7.92 | -- | 0.0981 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
Collegium Pharmaceutical Inc | 566.92m | 93.29m | 1.04bn | 197.00 | 15.51 | 4.70 | 4.36 | 1.84 | 2.06 | 2.06 | 12.06 | 6.79 | 0.4869 | 7.07 | 3.20 | 2,877,782.00 | 8.01 | 2.79 | 12.70 | 4.80 | 60.01 | 50.88 | 16.46 | 5.16 | 1.14 | 3.10 | 0.7372 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
Innoviva Inc | 311.59m | 181.39m | 1.09bn | 112.00 | 7.84 | 1.56 | 4.96 | 3.50 | 2.23 | 2.23 | 3.88 | 11.21 | 0.2599 | 0.9935 | 4.10 | 2,782,054.00 | 15.13 | 26.24 | 15.57 | 28.53 | 86.12 | -- | 58.21 | 76.84 | 9.17 | -- | 0.3883 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
Holder | Shares | % Held |
---|---|---|
Caligan Partners LPas of 20 Jun 2024 | 11.28m | 14.77% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 3.39m | 4.43% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.77m | 3.62% |
Kynam Capital Management LPas of 31 Mar 2024 | 2.25m | 2.94% |
Findell Capital Management LLCas of 31 Mar 2024 | 2.11m | 2.76% |
Farallon Capital Management LLCas of 31 Mar 2024 | 2.06m | 2.69% |
Vestal Point Capital LPas of 31 Mar 2024 | 2.00m | 2.62% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.23m | 1.61% |
Geode Capital Management LLCas of 31 Mar 2024 | 1.13m | 1.48% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 568.19k | 0.74% |